Rahul Bhambri
YOU?
Author Swipe
View article: Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real‐World Evaluation of Clinical Characteristics and Outcomes
Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real‐World Evaluation of Clinical Characteristics and Outcomes Open
Background The coexistence of transthyretin cardiac amyloidosis (ATTR‐CA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. We aimed to characterize clinical outcomes in AS plus ATTR‐CA compare…
View article: Supplementary materials: Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy
Supplementary materials: Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy Open
These are peer-reviewed supplementary tables for the article 'Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy' published in the Journal of Comparati…
View article: Artificial intelligence–enabled tools in cardiovascular medicine: A survey of current use, perceptions, and challenges
Artificial intelligence–enabled tools in cardiovascular medicine: A survey of current use, perceptions, and challenges Open
View article: Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States Open
View article: Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort Open
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, life-threatening condition that mostly affects older persons. In May 2019, regulatory approval of tafamidis provided the first pharmacologic treatment …
View article: Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database
Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database Open
These results provide evidence that real-world adherence to tafamidis in patients with ATTR-CM is high.
View article: Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy Open
View article: Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population
Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population Open
View article: Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy Open
Aim: Delayed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) represents a missed opportunity for intervention. This study estimates the health benefits of timely diagnosis and treatment with tafamidis. Methods: A disease simula…
View article: Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies Open
Aim The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This…
View article: Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review
Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review Open
View article: PRO5 Estimating the Health Benefits of Earlier Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy
PRO5 Estimating the Health Benefits of Earlier Diagnosis and Treatment of Transthyretin Amyloid Cardiomyopathy Open
View article: Risk of medication overuse headache across classes of treatments for acute migraine
Risk of medication overuse headache across classes of treatments for acute migraine Open
View article: A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine
A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine Open
Migraine is a commonly occurring, chronic disorder that can cause significant disability. Eletriptan, a selective serotonin 5-hydroxytryptamine 1 receptor subtype B/D (5-HT1B/1D) agonist, is a clinically effective treatment for moderate to…